BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qin Y, Yang G, Li M, Liu HJ, Zhong WL, Yan XQ, Qiao KL, Yang JH, Zhai DH, Yang W, Chen S, Zhou HG, Sun T, Yang C. Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway. Oncotarget 2017;8:103815-27. [PMID: 29262602 DOI: 10.18632/oncotarget.21793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liang W, Liu J, Wu H, Qiao X, Lu X, Liu Y, Zhu H, Ma L. Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines. Oncol Lett 2019;18:3407-14. [PMID: 31452821 DOI: 10.3892/ol.2019.10608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 He Y, Zhang Q, Chen H, Guo Q, Zhang L, Zhang Z, Li Y. Astragaloside IV enhanced carboplatin sensitivity in prostate cancer by suppressing AKT/NF-κB signaling pathway. Biochem Cell Biol 2021;99:214-22. [PMID: 32813978 DOI: 10.1139/bcb-2020-0026] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li Q, Ma Q, Cheng J, Zhou X, Pu W, Zhong X, Guo X. Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies. Onco Targets Ther 2021;14:2563-73. [PMID: 33880035 DOI: 10.2147/OTT.S297785] [Reference Citation Analysis]
4 Yang L, Zhang XY, Li K, Li AP, Yang WD, Yang R, Wang P, Zhao ZH, Cui F, Qin Y, Yang JH, Tao HL, Sun T, Chen S, Yu PH, Liu HJ, Yang C. Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway. Cell Death Dis 2019;10:630. [PMID: 31431619 DOI: 10.1038/s41419-019-1733-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
5 Li Y, Zhou X, Liu J, Yuan X, He Q. Therapeutic Potentials and Mechanisms of Artemisinin and its Derivatives for Tumorigenesis and Metastasis. Anticancer Agents Med Chem 2020;20:520-35. [PMID: 31958040 DOI: 10.2174/1871520620666200120100252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Abba ML, Patil N, Leupold JH, Saeed ME, Efferth T, Allgayer H. Prevention of carcinogenesis and metastasis by Artemisinin-type drugs. Cancer Letters 2018;429:11-8. [DOI: 10.1016/j.canlet.2018.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
7 Lu BW, Baum L, So KF, Chiu K, Xie LK. More than anti-malarial agents: therapeutic potential of artemisinins in neurodegeneration. Neural Regen Res 2019;14:1494-8. [PMID: 31089038 DOI: 10.4103/1673-5374.255960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Qin Y, Liu HJ, Li M, Zhai DH, Tang YH, Yang L, Qiao KL, Yang JH, Zhong WL, Zhang Q, Liu YR, Yang G, Sun T, Yang C. Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway. EBioMedicine 2018;38:25-36. [PMID: 30396856 DOI: 10.1016/j.ebiom.2018.10.069] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
9 Lin L, Li X, Pan C, Lin W, Shao R, Liu Y, Zhang J, Luo Y, Qian K, Shi M, Bin J, Liao Y, Liao W. ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance. Cell Death Dis 2019;10:173. [PMID: 30787271 DOI: 10.1038/s41419-019-1362-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
10 Tao J, Tan Z, Diao L, Ji Z, Zhu J, Chen W, Hu Y. Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancer via the NF-κB/MMP-2 signal pathway. RSC Adv 2018;8:21735-44. [DOI: 10.1039/c8ra02833h] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]